Note: Please read our disclaimer at the bottom of the article.
#StrongHands 🙌 #BOP 🚀 Nation Update ️️️️️️️️️️️️️️️️️️️❤️️
Hi, I’m Paul Mampilly.
Welcome to my company's Substack, where we provide daily coverage of #OGI (opportunity, growth, and innovation) market trends, macro level analysis, and stock picks.
Like our name suggests, at ATG Digital, we go Against the Grain to support everyday people on their investing journeys.
ATG also represents seeing the world for what is abundantly clear to see — an opportunity for incredible growth and the BRIGHT and PROSPEROUS future that lies ahead.
To aid you on your journey to financial freedom, we have five paid plans starting at $9.99 for you to consider.
With a subscription you get:
Premium Content: Weekly market and stock updates via email newsletter.
Stock Picking Guidance: Flash (buy/sell) alerts with targeted price points.
Model Portfolio Access: Access to LIVE portfolios.
Webinars: Private events with the team based on ideas preselected by you.
(Purple Tier Members)
Just visit atgdigital.media to see which plan is the best fit for your journey!
Substack 🥞 subscribers: 5,779
Bitcoin Halving Countdown ⏰
The Bitcoin USD (BTC-USD) halving is nearly upon us! We only have 17 days remaining!
That’s an event where BTC’s daily issuance/supply will be cut in half from 6.25 to 3.125.
As this happens, the remaining supply of BTC will become scarcer, which is bullish for crypto and related stocks!
This event only happens every four years, so we thought it fitting to ring in this crypto holiday with you! ❤️
Book 📖 Giveaway
Our giveaway is still ongoing! 👀
At the end of it, three lucky winners will receive a copy of Paul’s book, Profits Unlimited.
Entering is easy! All you have to do is like or share this week’s Substack posts.
One point will be awarded for liking a post, while five points will be awarded for sharing it. 👍
These points can be earned the entire duration of the giveaway!
Random winners will be selected, but those with the most points at the end of the week will have a better chance of winning . . .
And already, we’re seeing a great response from you, ATG Nation! 💪
Yesterday’s Substack received 20 likes — and of those subscribers, six shared to boost their odds!
Remember, our winners will be announced on Monday, April 8. 🎊
To start racking up points, click on the button below. 👇
Dan: 1 Small Company Set to Explode 💥
Here at ATG Digital, we follow companies demonstrating innovation and growth!
We fill our model portfolios with companies that we believe have potential to lead their sectors in the future.
Investing in small companies early gives you the highest potential for big returns.
We have a few model portfolios at ATG, each pursuing different opportunities — but the bottom line is that we’re all-in on growth and innovation.
Our Diamond Tier model portfolio focuses on small companies that could explode higher, bringing triple-digit or even quadruple-digit gains.
Today, I’ll discuss one company that could do just that!
1 Sector for the Bull 🐂 Run
The biopharmaceutical industry is set to soar.
Paul and I have been saying that we believe the biopharmaceutical sector will be a leader in this bull run.
Technological advancements in this sector have matured to a previously unimaginable state.
However, with the overall market in a downtrend, many of these companies have seen stock prices decline, irrespective of the company’s prospects and amazing technology/solutions.
But we’re in the midst of an incredible shift and believe our thesis is playing out!
We’re Up 30% on THIS Biotech 🧬
Last month, we added Atossa Therapeutics Inc. (Nasdaq: ATOS) to our Diamond Tier model portfolio.
So far, we’re up 30% in this position.
ATOS is a biopharmaceutical company dedicated to discovering and developing innovative therapeutics for breast cancer and other conditions.
And its lead breast cancer candidate, Endoxifen, could be a game-changer.
Endoxifen has shown promising results in early clinical trials, demonstrating its efficacy in hormone receptor-positive breast cancer, a common subtype of the disease.
With its unique mechanism of action and potential to improve patient outcomes, Endoxifen represents a significant opportunity for ATOS to address an unmet medical need.
Recently, ATOS announced that a patient, who received Endoxifen therapy under an FDA-approved "expanded access" program, has completed five years of treatment.
As of today, the patient remains cancer-free and reported no significant safety or tolerability issues throughout her treatment.
Risk for Reward 💰
ATOS is a clinical-stage biopharmaceutical company with no revenue. Companies like this are often very cheap and often risky.
With just a $254 million market cap, ATOS has $94 million in cash.
In our opinion, ATOS could do very well, bringing in revenue with its Endoxifen treatment. Alternatively, a bigger pharmaceutical company could acquire it.
Either of these scenarios will draw in investors, potentially leading to the stock price continuing to be bid up.
Positioned for Success 💪
With a promising pipeline of novel therapeutics, strategic partnerships, a focus on precision medicine, and a strong management team, ATOS is well-positioned for success in the rapidly evolving healthcare landscape.
As the company continues to advance its therapies through clinical development and commercialization, investors could benefit from potential value appreciation and significant returns on investment.
We’ll continue to hold ATOS in our Diamond Tier model portfolio.
But this isn’t our only incredible biotech stock . . .
For more opportunities like it — along with trade alerts and weekly updates — consider subscribing to our ATG Digital services by clicking here.
Subscriptions start at just $9.99!
#GBC100: Tuesday, April 2, 2024
The #GBC100 is down 1.76% today.
With markets shifting in our direction, there isn’t anything new to write about. So, just to let you know, we won’t always be commenting on the performance of the #GBC100 daily.
However, we’ll be updating the performance, and we want to remind folks that our goal is to turn the #GBC100 into an ETF that offers a one-stock way to invest the ATG way — in innovation and growth.
To learn more or express your support for the launch of an ETF (by completing a poll), click here.
Tomorrow: Dean will discuss one crypto making headlines. 📰 Stay tuned!
Today, Paul went live on our YouTube channel to talk about what we’re currently seeing in the market . . .
Specifically, what’s going on with Tesla Inc. (Nasdaq: TSLA) and Bitcoin USD (BTC-USD). 👀
If you weren’t able to tune in live, be sure to watch the video above! 👆
On Tuesday, April 2, 2024, we hope you find this information helpful as you navigate the market!
❤️️ This Substack made — by US, for YOU — with love. ❤️️
Questions? Concerns? 🤔 Look Below 👇
Have questions or trouble accessing your account? Please reach out to us at info@atgdigital.media or schedule a call, and our Customer Support team will be happy to help.
You can also check our FAQ page on our website for an up-to-date list of questions and answers. Your question may have been addressed there.
*Please be advised that customer support calls are limited to 15 minutes and will strictly cover your membership subscription and billing needs only. Any calls that are disrespectful in nature may be subject to immediate termination.
Join us, be #BOP 🚀, be #StrongHands 🙌, #GoATG! ️️❤️️
Disclaimer/Legal Stuff Written in Plain English
What you read/watch/hear is OPINION, not financial/investment advice. Treat it no different than when you read/watch/hear your favorite author/YouTuber/podcaster. Despite our best efforts, we get things wrong and make mistakes. Investing is risky. There is no guarantee you will make money. Your investments may lose value. That’s RISK. Past performance is no guarantee of future results. Employees, contractors, and owners of ATG Digital, LLC own/trade/transact in the stocks, options, and crypto that are the subject of our trade alerts, updates, reports, and commentaries. We cannot give you personalized financial advice because we are NOT financial advisors. It’s on you to decide how much/when/what to buy/sell based on YOUR financial needs, plans, and risk preferences. There are no guarantees. Loss of your capital is an outcome that you should evaluate carefully with a financial advisor before you trade, speculate, or invest. It's your money and your responsibility.